Sector: MedicalAFFY (NASDAQ: AFFY)
Headlines
- Affymax Prices Public Offering of Common Stock
Nov 19, 2009 09:01 AM | AFFY
- Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program
Nov 10, 2009 08:01 AM | AFFY
- Affymax and Takeda Announce Hematide(TM) Publication in the New England Journal of Medicine
Nov 04, 2009 05:00 PM | AFFY
- Affymax(R) Reports Third Quarter 2009 Financial Results
Nov 04, 2009 07:30 AM | AFFY
- Affymax Names Hollings C. Renton Chairman of the Board of Directors
Nov 03, 2009 10:30 AM | AFFY
- Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide(TM) Increased Hemoglobin in Dialysis Patients
Oct 30, 2009 02:00 PM | AFFY
- Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
Sep 09, 2009 08:01 AM | AFFY
- Affymax Announces Upcoming Webcasts and Conference Participation
Sep 03, 2009 04:00 PM | AFFY, MS
- FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, VPHM
Jun 04, 2009 06:41 PM | ABT, AFFY, AZN, LLY, MELA, PFE
- Periodicals Wrap-Up for Monday, August 11th
Aug 11, 2008 10:28 AM | AAPL, ABB, ACL, ADBE, ADM, AFFY
- Big Deals to Reshape Bay Area Biotech
Mar 12, 2009 08:51 PM | AFFY, CVTX, DNA, EXEL, GILD, JEF
- Big Deals Reshape Bay Area Biotech Industry
Mar 12, 2009 11:51 AM | AFFY, CVTX, DNA, EXEL, GILD, PFE
- Affymax Announces Proposed Public Offering of Common Stock
Nov 18, 2009 08:51 PM | AFFY
- Affymax® Reports Third Quarter 2009 Financial Results
Nov 04, 2009 07:51 AM | AFFY
- Affymax Secures $60 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
Sep 25, 2009 09:53 AM | AFFY
- Affymax® Reports Second Quarter 2009 Financial Results
Aug 05, 2009 08:08 AM | AFFY
- Affymax Announces Data Monitoring Committee Review of Phase 3 Hematide Program
Jul 20, 2009 08:05 AM | AFFY
- Affymax Appoints Hollings C. Renton to Board of Directors
Jun 10, 2009 10:18 AM | AFFY
- Affymax Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
Jun 03, 2009 08:10 AM | AFFY
- Affymax® Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient Baseline Renal Function
May 26, 2009 04:02 PM | AFFY
- Affymax® Reports First Quarter 2009 Financial Results
May 07, 2009 08:08 AM | AFFY
- Affymax Reports Phase 2 Sub-Analysis of Hematide™ in Hemodialysis Patients
Mar 27, 2009 07:03 AM | AFFY
- Form 4 AFFYMAX INC For: Nov 10 Filed by: Duliege Anne-Marie (10K)
Nov 12, 2009 01:47 PM
- Form 4 Morris Arlene For: Sep 28 (10K)
Sep 30, 2009 08:17 PM
- Form 4 AFFYMAX INC For: Sep 16 Filed by: APAX PARTNERS EUROPE MANAGERS LTD (10K)
Sep 18, 2009 08:11 PM
- Form 4 APAX MANAGERS INC For: Sep 16 (10K)
Sep 18, 2009 08:10 PM
- Form 4 APAX MANAGERS INC For: Sep 14 (10K)
Sep 16, 2009 08:09 PM
- Form 4 AFFYMAX INC For: Sep 14 Filed by: APAX PARTNERS EUROPE MANAGERS LTD (10K)
Sep 16, 2009 08:09 PM
- Form 4 APAX MANAGERS INC For: Sep 11 (10K)
Sep 15, 2009 08:08 PM
- Form 4 AFFYMAX INC For: Sep 11 Filed by: APAX PARTNERS EUROPE MANAGERS LTD (10K)
Sep 15, 2009 08:08 PM
- Form 4 Duliege Anne-Marie For: Sep 03 (10K)
Sep 03, 2009 10:43 PM
- Form 4 AFFYMAX INC For: Sep 01 Filed by: APAX PARTNERS EUROPE MANAGERS LTD (10K)
Sep 03, 2009 08:08 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
AFFY
|
Compare to S&P
|
| YTD |
100.10 %
|
65.29 %
|
| 4 Weeks |
-17.77 %
|
-18.21 %
|
| 12 Weeks |
-6.15 %
|
-11.93 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 17.09 %
|
|
EPS Growth in Last Year: 43.60 %
|
|
Sales Growth in Last Quarter: 8.31 %
|
|
Sales Growth in Last Quarter: 34.71 %
|
|
